litlas
Log inCreate account

Ingrid A. Mayer

Active 2000–2025

111
Papers
30,753
Citations
73
h-index
108
i10-index

Citations

Citations per year for Ingrid A. Mayer1981: 1 citations1984: 1 citations1993: 1 citations1996: 1 citations1999: 2 citations2001: 8 citations2002: 18 citations2003: 19 citations2004: 9 citations2005: 7 citations2006: 10 citations2007: 6 citations2008: 23 citations2009: 38 citations2010: 60 citations2011: 97 citations2012: 88 citations2013: 86 citations2014: 108 citations2015: 132 citations2016: 148 citations2017: 208 citations2018: 281 citations2019: 1,327 citations2020: 1,725 citations2021: 1,865 citations2022: 1,562 citations2023: 1,160 citations2024: 1,628 citations2025: 755 citations2026: 30 citations1982–1983: no citations, so these years are not shown1985–1992: no citations, so these years are not shown1994–1995: no citations, so these years are not shown1997–1998: no citations, so these years are not shown2000: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,794 citing papers, 24.9% of this breakdownChina: 2,308 citing papers, 15.1% of this breakdownItaly: 872 citing papers, 5.7% of this breakdownUnited Kingdom: 715 citing papers, 4.7% of this breakdownGermany: 662 citing papers, 4.4% of this breakdownFrance: 544 citing papers, 3.6% of this breakdownCanada: 517 citing papers, 3.4% of this breakdownSpain: 516 citing papers, 3.4% of this breakdownSouth Korea: 371 citing papers, 2.4% of this breakdownJapan: 364 citing papers, 2.4% of this breakdownAustralia: 340 citing papers, 2.2% of this breakdownSwitzerland: 324 citing papers, 2.1% of this breakdown
0%24.9%Other 25.7%

Institutions

Fields

  • Medicine51.2%
  • Biochemistry, Genetics and Molecular Biology39.7%
  • Immunology and Microbiology2.2%
  • Computer Science1.9%
  • Engineering1.3%
  • Chemistry0.8%
  • Other2.9%

Topics

  • Breast Cancer Treatment Studies6.8%
  • HER2/EGFR in Cancer Research5.9%
  • Advanced Breast Cancer Therapies5.1%
  • Cancer Genomics and Diagnostics3.3%
  • Cancer Cells and Metastasis2.4%
  • PI3K/AKT/mTOR signaling in cancer2.4%
  • Other74.1%

Coauthors

All papers

Open in search
  1. Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    Authors: Fabrice André, Eva Ciruelos, Gábor Rubovszky, Mario Campone, Sibylle Loibl, Hope S. Rugo, Hiroji Iwata, PierFranco Conte, Ingrid A. Mayer, Bella Kaufman, Toshinari Yamashita, Yen‐Shen Lu, Kenichi Inoue, Masato Takahashi, Zsuzsanna Pápai, Anne-Sophie Longin, David Mills, Celine Wilke, Samit Hirawat, Dejan Juric - New England Journal of Medicine 2019 cited by 2,572

  2. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

    Authors: Giampaolo Bianchini, Justin M. Balko, Ingrid A. Mayer, Melinda E. Sanders, Luca Gianni - Nature Reviews Clinical Oncology 2016 cited by 3,072

  3. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

    Authors: Joseph A. Sparano, Robert J. Gray, Della Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Matthew P. Goetz, John A. Olson, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, Soonmyung Paik, William C. Wood, Peter M. Ravdin, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, Jeffrey L. Berenberg, Jeffrey S. Abrams, George W. Sledge - New England Journal of Medicine 2018 cited by 2,369

  4. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

    Authors: Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff, Jennifer R. Diamond, Joyce O’Shaughnessy, Rebecca Moroose, Alessandro D. Santin, Vandana G. Abramson, Nikita Shah, Hope S. Rugo, David M. Goldenberg, Ala M. Sweidan, Robert Iannone, Sarah A. Washkowitz, Robert M. Sharkey, William A. Wegener, Kevin Kalinsky - New England Journal of Medicine 2019 cited by 850

  5. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

    Authors: William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen M. Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau T. Dang, Anthony Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice A. Lyons, P. Kelly Marcom, Jennifer M. Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth O’Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy M. Sitapati, Karen L. Smith, Mary Lou Smith, Hatem Soliman, Erica Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica Young, Jennifer L. Burns, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2020 cited by 1,618

  6. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

    Authors: Fabrice André, Eva Ciruelos, Dejan Juric, Sibylle Loibl, Mario Campone, Ingrid A. Mayer, Gábor Rubovszky, Toshinari Yamashita, Bella Kaufman, Yen‐Shen Lu, Kenichi Inoue, Zsuzsanna Pápai, Masato Takahashi, Farhat Ghaznawi, David Mills, Mathilde Kaper, Michelle C. Miller, PierFranco Conte, Hiroji Iwata, Hope S. Rugo - Annals of Oncology 2020 cited by 599

  7. Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer

    Authors: Pamela J. Goodwin, Bingshu E. Chen, Karen A. Gelmon, Timothy J. Whelan, Marguerite Ennis, Julie Lemieux, Jennifer A. Ligibel, Dawn L. Hershman, Ingrid A. Mayer, Timothy J. Hobday, Judith M. Bliss, Priya Rastogi, Manuela Rabaglio, Som D. Mukherjee, John R. Mackey, Vandana G. Abramson, Conrad D. Oja, Robert Wesolowski, Alastair M. Thompson, Daniel Rea, Paul M. Stos, Lois E. Shepherd, Vuk Stambolic, Wendy R. Parulekar - JAMA 2022 cited by 223

  8. HER kinase inhibition in patients with HER2- and HER3-mutant cancers

    Authors: David M. Hyman, Sarina A. Piha‐Paul, Helen Won, Jordi Rodón, Cristina Saura, Geoffrey I. Shapiro, Dejan Juric, David I. Quinn, Víctor Moreno, Bernard Doger, Ingrid A. Mayer, Valentina Boni, Emiliano Calvo, Sherene Loi, A. Craig Lockhart, Joseph P. Erinjeri, Maurizio Scaltriti, Gary A. Ulaner, Juber Patel, Jiabin Tang, Hannah Beer, S. Duygu Selçuklu, Aphrothiti J. Hanrahan, Nancy Bouvier, Myra Melcer, Rajmohan Murali, Alison M. Schram, Lillian M. Smyth, Komal Jhaveri, Bob T. Li, Alexander Drilon, James J. Harding, Gopa Iyer, Barry S. Taylor, Michael F. Berger, Richard E. Cutler, Feng Xu, Anna Butturini, Lisa D. Eli, Grace Mann, Cynthia Farrell, Alshad S. Lalani, Richard Bryce, Carlos L. Arteaga, Funda Meric‐Bernstam, José Baselga, David B. Solit - Nature 2018 cited by 788

  9. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

    Authors: Otto Metzger, Giuseppe Viale, Shayna Stein, Lorenzo Trippa, Denise A. Yardley, Ingrid A. Mayer, Vandana G. Abramson, Carlos L. Arteaga, Laura M. Spring, Adrienne G. Waks, Eileen Wrabel, Michelle K. DeMeo, Aditya Bardia, Patrizia Dell’Orto, Leila Russo, Tari A. King, Kornélia Polyák, Franziska Michor, Eric P. Winer, Ian E. Krop - Cancer Discovery 2021 cited by 240

  10. The PI3K/AKT Pathway as a Target for Cancer Treatment

    Authors: Ingrid A. Mayer, Carlos L. Arteaga - Annual Review of Medicine 2015 cited by 840

  11. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

    Authors: Michael Gnant, Amylou C. Dueck, Sophie Frantal, Miguel Martín, H.J. Burstein, Richard Greil, Peter Fox, Antonio C. Wolff, Arlene Chan, Eric P. Winer, Georg Pfeiler, Kathy D. Miller, Marco Colleoni, Jennifer M. Suga, Gabor Rubovsky, Judith M. Bliss, Ingrid A. Mayer, Christian F. Singer, Zbigniew Nowecki, Olwen Hahn, Jacqui Thomson, Norman Wolmark, Kepa Amillano, Hope S. Rugo, Guenther G. Steger, Blanca Hernando Fernández de Aranguiz, Tufia C. Haddad, Antonia Perelló, Meritxell Bellet, Hannes Fohler, Otto Metzger, Anita Jallitsch-Halper, Kadine Solomon, Céline Schurmans, K. P. Theall, Dongrui R. Lu, Kathleen Tenner, Christian Fesl, Angela DeMichele, Erica L. Mayer, on behalf of the PALLAS groups and investigators - Journal of Clinical Oncology 2021 cited by 231

  12. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

    Authors: Aditya Bardia, Ingrid A. Mayer, Jennifer R. Diamond, Rebecca Moroose, Steven J. Isakoff, Alexander Starodub, Nikita Shah, Joyce O’Shaughnessy, Kevin Kalinsky, Michael J. Guarino, Vandana G. Abramson, Dejan Juric, Sara M. Tolaney, Jordan Berlin, Wells A. Messersmith, Allyson J. Ocean, William A. Wegener, Pius Maliakal, Robert M. Sharkey, Serengulam V. Govindan, David M. Goldenberg, Linda T. Vahdat - Journal of Clinical Oncology 2017 cited by 409

  13. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

    Authors: Luigi Formisano, Yao Lu, Alberto Servetto, Ariella B. Hanker, Valerie M. Jansen, Joshua A. Bauer, Dhivya R. Sudhan, Ángel Guerrero‐Zotano, Sarah Croessmann, Yan Guo, Paula I. González-Ericsson, Kyung‐min Lee, Mellissa J. Nixon, Luis J. Schwarz, Melinda E. Sanders, Teresa C. Dugger, Marcelo Cruz, Amir Behdad, Massimo Cristofanilli, Aditya Bardia, Joyce O’Shaughnessy, Rebecca J. Nagy, Richard B. Lanman, Nadia Solovieff, Wei He, Michelle C. Miller, Fei Su, Yu Shyr, Ingrid A. Mayer, Justin M. Balko, Carlos L. Arteaga - Nature Communications 2019 cited by 419

  14. Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics

    Authors: Allyson J. Ocean, Alexander Starodub, Aditya Bardia, Linda T. Vahdat, Steven J. Isakoff, Michael J. Guarino, Wells A. Messersmith, Vincent J. Picozzi, Ingrid A. Mayer, William A. Wegener, Pius Maliakal, Serengulam V. Govindan, Robert M. Sharkey, David M. Goldenberg - Cancer 2017 cited by 236

  15. Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer

    Authors: Sara Nunnery, Ingrid A. Mayer - Drugs 2020 cited by 202

  16. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

    Authors: Joseph A. Sparano, Robert J. Gray, Peter M. Ravdin, Della Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Matthew P. Goetz, John A. Olson, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, Soonmyung Paik, William C. Wood, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, Jeffrey L. Berenberg, Jeffrey S. Abrams, George W. Sledge - New England Journal of Medicine 2019 cited by 555

  17. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

    Authors: Joseph A. Sparano, Robert J. Gray, Della Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Edith A. Perez, John A. Olson, JoAnne Zujewski, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, Soonmyung Paik, William C. Wood, Peter M. Ravdin, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, James N. Atkins, Jeffrey L. Berenberg, George W. Sledge - New England Journal of Medicine 2015 cited by 1,439

  18. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gϋnter von Minckwitz, Stephen Chia, Janine Mansi, Carlos H. Barrios, Michael Gnant, Z. Tomasevic, Neelima Denduluri, Robert Šeparović, Erhan Gökmen, Anna Bashford, Manuel Ruíz Borrego, Sung‐Bae Kim, Erik Jakobsen, A. Ciceniene, Kenichi Inoue, Friedrich Overkamp, Joan B. Heijns, Anne Armstrong, John S. Link, Anil A. Joy, Richard Bryce, Alvin Wong, Susan Moran, Bin Yao, Feng Xu, Alan Auerbach, Marc Buyse, Arlene Chan, Vernon Harvey, Rudolf Tomek, Nicholas J. Robert, Ira Gore, John W. Smith, Norikazu Masuda, S. Di Sean Kendall, William Graydon Harker, Katarína Petráková, Ángel Guerrero‐Zotano, Amparo Ruiz Simón, Zora Neskovic Konstantinovic, Nicholas Iannotti, Pierfrancesco Tassone, Gladys Rodriguez, Noelia Jáñez Martínez, Carmen Crespo Massieu, Snezana Smickoska, Işıl Somali, Uğur Yılmaz, Mirta Garcia Alonso, Adolfo Rosales, Soeren Cold, Ann Knoop, Debra A. Patt, Beth A. Hellerstedt, Serafin Morales Murillo, Ingrid A. Mayer, Julie A. Means‐Powell, Rina Hui, Francis M. Senecal, Richard Hendry De Boer, Zhenzhou Shen, A.A. Luczak, Joanna W.Y. Chui, Janice Tsang, István Láng, Yoshiaki Rai, Yasuo Hozumi, Albert J. ten Tije, Manish Bhandari, Cynthia R. Osborne, Shoichiro Ohtani, Kenji Higaki, Kenichi Watanabe, Kazunori TAGUCHI, Masato Takahashi, Sladjana Filipovic, Vincent Hansen, Vijayarama Phooshkooru Rao, Manish Gupta, Petar Petrov, Bruno Coudert, Željko Vojnović, Zsofia Polya, Toshiko Miyaki, Naohito Yamamoto, Stephen Brincat, Krzysztof Leśniewski-Kmak, Ewa Chmielowska, Ruemu Birhiray, Marc L. Citron, Steven W. Papish, William L. Berry, Sven Tyge Langkjer, José Á. García-Sáenz and 526 more - The Lancet Oncology 2017 cited by 589

  19. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

    Authors: Hope S. Rugo, Fabrice André, Toshinari Yamashita, Humberto Cerda, I. Toledano, Salomon M. Stemmer, Josefina Cruz Jurado, Dejan Juric, Ingrid A. Mayer, Eva Ciruelos, Hiroji Iwata, PierFranco Conte, Mario Campone, C. Wilke, David Mills, Agnes Lteif, Michelle C. Miller, Fiorenza Gaudenzi, Sibylle Loibl - Annals of Oncology 2020 cited by 187

  20. Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer

    Authors: Dejan Juric, Filip Jankú, Jordi Rodón, Howard A. Burris, Ingrid A. Mayer, Martin Schüler, Ruth Seggewiss‐Bernhardt, Marta Gil-Martín, Mark R. Middleton, José Baselga, Douglas Bootle, David Demanse, Lars Blumenstein, Karl Schumacher, Alan Huang, Cornelia Quadt, Hope S. Rugo - JAMA Oncology 2018 cited by 260

  21. Resistance to Trastuzumab in Breast Cancer

    Authors: Paula R. Pohlmann, Ingrid A. Mayer, Ray Mernaugh - Clinical Cancer Research 2009 cited by 507

  22. Management of toxicity to isoform α-specific PI3K inhibitors

    Authors: Sara Nunnery, Ingrid A. Mayer - Annals of Oncology 2019 cited by 135

  23. NCCN Guidelines Insights: Breast Cancer, Version 1.2017

    Authors: William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice A. Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth O’Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth Reed, Kilian Salerno, Lee S. Schwartzberg, Amy M. Sitapati, Karen L. Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Dorothy A. Shead, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2017 cited by 542

  24. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment

    Authors: Ángel Guerrero‐Zotano, Ingrid A. Mayer, Carlos L. Arteaga - Cancer and Metastasis Reviews 2016 cited by 437